Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

A small papillary thyroid cancer study demonstrates favorable outcomes and highlights the role of American Thyroid ...

Early-life exposure to fine particulate matter (PM2.5) and outdoor artificial light at night (O-ALAN) is associated with ...

Rather than tumor size alone, the American Thyroid Association’s risk stratification system should be used when assessing ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® ...